Last reviewed · How we verify
Ifosfamide, Gemcitabine, Vinorelbine
At a glance
| Generic name | Ifosfamide, Gemcitabine, Vinorelbine |
|---|---|
| Sponsor | Istituto Clinico Humanitas |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents (PHASE2)
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer (PHASE1)
- Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL (PHASE2)
- A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma (PHASE2)
- A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma (PHASE3)
- Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ifosfamide, Gemcitabine, Vinorelbine CI brief — competitive landscape report
- Ifosfamide, Gemcitabine, Vinorelbine updates RSS · CI watch RSS
- Istituto Clinico Humanitas portfolio CI